Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is a promising company with a strong financial outlook and a positive market potential for its novel metabolic therapies. With a successful gene therapy trial for Type 2 Diabetes expected in 2026 and additional candidates in the pipeline, Fractyl Health has potential for higher market penetration and revenue through commercialization in multiple geographic regions. Despite risks, the company's new drug pricing strategies and the possibility of a RAPID coverage pathway could drive growth and solidify its position as a pioneer in treating the root causes of metabolic diseases.

Bears say

Fractyl Health is facing potential issues with gaining physician training and familiarity for their procedures, as well as challenges with weight maintenance for patients receiving less than 14 cm ablations. The company's recent data shows a significant correlation between ablation length and weight maintenance, with patients receiving >14 cm ablations regaining ~50% the weight of sham at six months. Despite a sharp negative market reaction to the REMAIN-1 midpoint readouts, the company remains optimistic about the pivotal readout anticipated in 4Q26, with a projected price target of $8 per share based on a sum-of-the-parts analysis focused on Revita and Rejuva peak sales.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of Sep 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.